374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

• Howard Streicher,
• Michael Manos,
• Philippe Bedard,
• Osama Rahma,
• Andrew Brohl,
• Kevin Tyan,
• Scott Rodig,
• Daniel Renouf,
• Emma Hathaway,
• Rachel Cunningham

Affiliations

Howard Streicher

Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA

Michael Manos

Dana Farber Cancer Institute, Boston, Massachusetts, USA

Philippe Bedard

Aff46 0000 0001 2150 066Xgrid.415224.4Princess Margaret Cancer Centre Toronto ON Canada

Osama Rahma

Center for Cancer Therapeutic Innovation, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Andrew Brohl

4H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Kevin Tyan

1Harvard Medical School, Somerville, MA, USA

Scott Rodig

7Brigham and Women’s Hospital and Harvard, Boston, MA, USA

Daniel Renouf

2The University of British Columbia, Vancouver, British Columbia, Canada

Emma Hathaway

3Dana-Farber Cancer Institute, Boston, MA, USA

Rachel Cunningham

3Dana-Farber Cancer Institute, Boston, MA, USA